Showing 1,081 - 1,100 results of 104,039 for search '(( 2 wt decrease ) OR ( 5 ((we decrease) OR (((nn decrease) OR (a decrease)))) ))', query time: 1.56s Refine Results
  1. 1081
  2. 1082
  3. 1083
  4. 1084

    Heterologous Immunity Triggered by a Single, Latent Virus in <i>Mus musculus</i>: Combined Costimulation- and Adhesion- Blockade Decrease Rejection by Jonathan M. Beus (441623)

    Published 2013
    “…<div><p>The mechanisms underlying latent-virus-mediated heterologous immunity, and subsequent transplant rejection, especially in the setting of T cell costimulation blockade, remain undetermined. To address this, we have utilized MHV68 to develop a rodent model of latent virus-induced heterologous alloimmunity. …”
  5. 1085
  6. 1086

    Albumin Decrease Is Associated with Spontaneous Preterm Delivery within 48 h in Women with Threatened Preterm Labor by Yujing J. Heng (1696339)

    Published 2015
    “…SWATH methodology quantified 258 proteins (using ≥2 peptides) and 5 proteins (ALBU, ANXA6, HNRPK, HSP90A, and PDIA1) were differentially expressed (<i>p</i> < 0.05, Mann–Whitney <i>U</i>). iTRAQ workflow identified 765 proteins; 354 proteins were quantified and 14 proteins (MIF, UBIQ, HXK3, ALBU, HNRPD, ST1A2, RS15A, RAP1B, CAN1, IQGA2, ST1A1, COX5A, ADDA, and UBQL1) were significantly different between the two groups of women (<i>p</i> < 0.05, Mann–Whitney <i>U</i>). …”
  7. 1087

    Albumin Decrease Is Associated with Spontaneous Preterm Delivery within 48 h in Women with Threatened Preterm Labor by Yujing J. Heng (1696339)

    Published 2015
    “…SWATH methodology quantified 258 proteins (using ≥2 peptides) and 5 proteins (ALBU, ANXA6, HNRPK, HSP90A, and PDIA1) were differentially expressed (<i>p</i> < 0.05, Mann–Whitney <i>U</i>). iTRAQ workflow identified 765 proteins; 354 proteins were quantified and 14 proteins (MIF, UBIQ, HXK3, ALBU, HNRPD, ST1A2, RS15A, RAP1B, CAN1, IQGA2, ST1A1, COX5A, ADDA, and UBQL1) were significantly different between the two groups of women (<i>p</i> < 0.05, Mann–Whitney <i>U</i>). …”
  8. 1088

    Image 2_Probiotic Limosilactobacillus reuteri KUB-AC5 decreases urothelial cell invasion and enhances macrophage killing of uropathogenic Escherichia coli in vitro study.tiff by Arishabhas Tantibhadrasapa (13929639)

    Published 2024
    “…The human bladder epithelial cell line UM-UC-3 was used to assess the adhesion and pathogen-attachment inhibition properties of AC5 on UPEC.</p>Results and discussion<p>Our data showed that AC5 can attach to UM-UC-3 and decrease UPEC attachment in a dose-dependent manner. …”
  9. 1089

    Table 1_Probiotic Limosilactobacillus reuteri KUB-AC5 decreases urothelial cell invasion and enhances macrophage killing of uropathogenic Escherichia coli in vitro study.xlsx by Arishabhas Tantibhadrasapa (13929639)

    Published 2024
    “…The human bladder epithelial cell line UM-UC-3 was used to assess the adhesion and pathogen-attachment inhibition properties of AC5 on UPEC.</p>Results and discussion<p>Our data showed that AC5 can attach to UM-UC-3 and decrease UPEC attachment in a dose-dependent manner. …”
  10. 1090

    Image 1_Probiotic Limosilactobacillus reuteri KUB-AC5 decreases urothelial cell invasion and enhances macrophage killing of uropathogenic Escherichia coli in vitro study.tiff by Arishabhas Tantibhadrasapa (13929639)

    Published 2024
    “…The human bladder epithelial cell line UM-UC-3 was used to assess the adhesion and pathogen-attachment inhibition properties of AC5 on UPEC.</p>Results and discussion<p>Our data showed that AC5 can attach to UM-UC-3 and decrease UPEC attachment in a dose-dependent manner. …”
  11. 1091
  12. 1092
  13. 1093

    Fig 5 - by Geoff Harley (14593275)

    Published 2023
    “…There was no significance difference between WT and PFKFB2 KI mouse groups in any of these parameters measured. …”
  14. 1094
  15. 1095
  16. 1096
  17. 1097
  18. 1098

    A PPARα Promoter Variant Impairs ERR-Dependent Transactivation and Decreases Mortality after Acute Coronary Ischemia in Patients with Diabetes by Sharon Cresci (53599)

    Published 2010
    “…Consistent with previous descriptions of PPARα in experimental models and human disease, we describe a novel <em>PPARA</em> promoter SNP that decreases transcriptional activation of <em>PPARA</em> and protects against mortality in diabetic patients after ACS.…”
  19. 1099
  20. 1100